Le Lézard
Classified in: Ebola virus, Health, Science and technology
Subjects: CCA, BFA

Aethlon Medical to Release Financial Results for the Second Quarter Fiscal Year 2018 and Host Conference Call on November 2, 2017



SAN DIEGO, Oct. 30, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial results for the second quarter fiscal year 2018 ended September 30, 2017 at 4:15pm eastern time on Thursday, November 2, 2017.

Management will host a conference call on Thursday, November 2, 2017 at 4:30pm eastern time to review financial results and corporate highlights. Following management's formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and International callers should call 1-412-317-5442. All callers should ask for the Aethlon Medical Inc., conference call. The conference call will also be available through a live webcast at www.aethlonmedical.com. Details for the webcast may be found on the Company's IR events page at http://ir.aethlonmedical.com.

A replay of the call will be available approximately one hour after the end of the call through November 9, 2017. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada Toll Free at 1-855-669-9658. The replay conference ID number is 10114031.

About Aethlon Medical, Inc.

Aethlon Medical is focused on addressing unmet needs in global health and biodefense. The Aethlon Hemopurifier® is a first-in-class therapeutic device designed to address life-threatening viral infections.  The United States Food and Drug Administration (FDA) has designated the Hemopurifier® to an Expedited Access Pathway (EAP) related to the treatment of life-threatening viruses that are not addressed with approved therapies.

In collaboration with leading government and non-government research institutes, Aethlon has validated the ability of the Hemopurifier® to capture a broad-spectrum of pandemic influenza viruses, mosquito-borne viruses and deadly hemorrhagic viruses.  Based on its use to treat Ebola virus, the Hemopurifier® was named a "Top 25 Invention" and one of the "Eleven Most Remarkable Advances in Healthcare," by TIME Magazine.

Aethlon is also investigating the potential therapeutic use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.  Additionally, Aethlon is the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE).  Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.  You can also connect with us on Twitter, LinkedIn, Facebook and Google+.

Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 extension 3300
Jfrakes@aethlonmedical.com

Investor Relations:
John Marco
CORE IR
516 222 2560
johnm@coreir.com

 

SOURCE Aethlon Medical, Inc.


These press releases may also interest you

15 nov 2018
This report analyzes the worldwide markets for Human Vaccines in US$ Million by the following Product Segments: Pediatric Vaccines, and Adult Vaccines.Read the full report: https://www.reportlinker.com/p05621724 The report provides separate...

14 nov 2018
The proliferation of online medical information has affected the frequency and nature of patient/physician interactions, according to the findings of a survey released today by the Merck Manuals, one of the world's most widely-used medical resources...

13 nov 2018
The "Mixed Mode Chromatography Resin Market Analysis Report By Technique (Ion exchange - Hydrophobic, Hydroxyapatite), By End Use (Pharmaceutical & Biotechnology), And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's...

12 nov 2018
100 Connected Car Companies to Watch  Analysis of Leading Suppliers & OEMs Involved in Tethered, Integrated & Embedded Solutions, In-Vehicle Technologies (IN-V), Telematics, Infotainment, Diagnostics, Connectivity, Safety, Navigation, UBI, Security...

12 nov 2018
SKF is investing SEK 200 million in upgrading and modernizing its logistics and bearing remanufacturing centres in St Cyr, France. The logistics centre investment improves customer service levels and lead-times by bringing component storage from all...

9 nov 2018
Today, the U.S. Food and Drug Administration announced that an emergency use authorization (EUA) has been issued for a rapid, single-use test for the detection of Ebola virus (Zaire ebolavirus). This is the second Ebola rapid antigen fingerstick test...




News published on 30 october 2017 at 07:30 and distributed by: